TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8155034

Group type: EXPERIMENTAL
Intervention: Methazolamide (50 mg twice daily) for 6 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Methazolamide (50 mg twice daily) for 12 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Best corrected visual acuity assessment
Number of subjects: 17
Study: 3020692

Group type: EXPERIMENTAL
Intervention: CAV alternating with VP-16 plus cisplatin for a total of six treatment cycles
Number of subjects: 0

Group type: COMPARATOR
Intervention: CAV (standard regimen)
Number of subjects: 0
Study: 31610074

Group type: EXPERIMENTAL
Intervention: Fitbit
Number of subjects: 47

Group type: COMPARATOR
Intervention: Smartphone app
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Reviewing symptoms weekly
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Preference for reviewing symptoms
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Monitoring sleep
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Barriers to self-monitoring
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Reasons for self-monitoring
Number of subjects: 47
Study: 29398910

Group type: EXPERIMENTAL
Intervention: PEM-NWE
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PEM-PRE
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 75
Study: 27388859

Group type: EXPERIMENTAL
Intervention: Mastery training intervention for video laryngoscopy (VL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group receiving mastery training after 3 months
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall attempts to demonstrate mastery
Number of subjects: 35
Study: 24485549

Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver dressing (Acticoat™)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Plain gauze dressing (control)
Number of subjects: 76
Study: 23164205

Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine
Number of subjects: 376

Group type: COMPARATOR
Intervention: Bacteriostatic normal saline
Number of subjects: 376
Study: 20180607

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17936590

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Befriending (BF)
Number of subjects: 90
Study: 16075327

Group type: EXPERIMENTAL
Intervention: Unoprostone isopropyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11752037

Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid (GA) 1 g/d
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 10432909

Group type: EXPERIMENTAL
Intervention: Abuse assessment protocol
Number of subjects: 540

Group type: COMPARATOR
Intervention: No abuse assessment protocol (control)
Number of subjects: 540
Study: 7487504

Group type: EXPERIMENTAL
Intervention: Early physical conditioning (PC) started 15 days after MRS, with a training intensity up to five metabolic units, three times a week for 1 hour and 15 minutes.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Physical conditioning (PC) started 3 months after MRS, with a training intensity of about 70% of the maximum heart rate reserve, three times a week for 1 hour.
Number of subjects: 22
Study: 2275253

Group type: EXPERIMENTAL
Intervention: Exclusion diet
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard diet (low in refined carbohydrates and rich in fiber)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both dietary groups (Exclusion diet and Standard diet)
Number of subjects: 26
Study: 6766274

Group type: EXPERIMENTAL
Intervention: Amoxicillin, 6 gm by mouth every 24 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aqueous penicillin G, 30 million units and gentamicin, 180 to 240 mg intravenously every 24 hours
Number of subjects: 30
Study: 30621764

Group type: EXPERIMENTAL
Intervention: Calmangafodipir (PP100‐01) co-administered with a 12-h NAC regimen
Number of subjects: 24

Group type: COMPARATOR
Intervention: NAC treatment alone
Number of subjects: 24
Study: 28738857

Group type: COMPARATOR
Intervention: Standard of Care (SOC) - invitation letter to male partner offering HIV testing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral HIV self-test kits (one of five intervention arms)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral HIV self-test kits with financial incentive (fixed or lottery amount)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral HIV self-test kits with phone call reminders
Number of subjects: 21
Study: 25994445

Group type: EXPERIMENTAL
Intervention: Group-mediated cognitive behavioral intervention promoting home-based unsupervised exercise
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group attending weekly lectures
Number of subjects: 194
Study: 24099350

Group type: EXPERIMENTAL
Intervention: Qishe Pill (3.75 g twice a day for 28 days)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (3.75 g twice a day for 28 days)
Number of subjects: 240
Study: 21216583

Group type: EXPERIMENTAL
Intervention: Chromium chloride 400 μg
Number of subjects: 25
Study: 20361676

Group type: EXPERIMENTAL
Intervention: Intramuscular iron sorbitol (IS)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Oral sodium iron edetate (SIE)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Oral iron polymaltose complex (IPC)
Number of subjects: 146
Study: 17899047

Group type: EXPERIMENTAL
Intervention: IDAS II
Number of subjects: 24

Group type: COMPARATOR
Intervention: MEMS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 24
Study: 15117055

Group type: EXPERIMENTAL
Intervention: Lutein 10 mg (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lutein 10 mg/antioxidants/vitamins and minerals broad spectrum supplementation formula (Group 2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Maltodextrin placebo (Group 3)
Number of subjects: 90
Study: 11605923

Group type: EXPERIMENTAL
Intervention: 5% albumin solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6% hetastarch solution
Number of subjects: 20
Study: 9210677

Group type: EXPERIMENTAL
Intervention: Cefdinir 600 mg once a day for 10 days
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg twice a day for 10 days
Number of subjects: 1798

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate 500 mg three times a day for 10 days
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Cefdinir (both dosages)
Number of subjects: 1798

Group type: COMPARATOR
Intervention: Cefdinir and Amoxicillin-clavulanate (both groups)
Number of subjects: 1798
Study: 7683742

Group type: EXPERIMENTAL
Intervention: Oral cotrimoxazole
Number of subjects: 105

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 105
Study: 3302923

Group type: EXPERIMENTAL
Intervention: Intervention group (39 mothers) received anticipatory guidance with discussions of developmental stages.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (44 mothers) received standard anticipatory guidance without developmental discussions.
Number of subjects: 83
Study: 2625689

Group type: EXPERIMENTAL
Intervention: BID salsalate (3500 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: BID naproxen (750 mg/day)
Number of subjects: 40
Study: 30936633

Group type: EXPERIMENTAL
Intervention: Ergometer cycling (60 minutes per session, 3 times per week for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional physiotherapy (same duration as experimental group)
Number of subjects: 20
Study: 27929693

Group type: EXPERIMENTAL
Intervention: New external fixators
Number of subjects: 95

Group type: COMPARATOR
Intervention: Recycled external fixators
Number of subjects: 95
Study: 26051796

Group type: EXPERIMENTAL
Intervention: Recruitment strategies including simplifying materials and tailoring recruitment activities to specific communities' needs.
Number of subjects: 96
Study: 23548990

Group type: EXPERIMENTAL
Intervention: Individually targeted physical activity counseling and supervised strength and balance training once a week.
Number of subjects: 559

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 559
Study: 21739683

Group type: EXPERIMENTAL
Intervention: Speech rehabilitation plus acupuncture (observation group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Speech rehabilitation plus acupuncture combined with psychotherapy (observation group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Speech rehabilitation (control group)
Number of subjects: 120
Study: 19453794

Group type: EXPERIMENTAL
Intervention: Etanercept therapy
Number of subjects: 711

Group type: COMPARATOR
Intervention: Paused therapy (control)
Number of subjects: 711
Study: 16923636

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 5 daily sessions)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 10
Study: 15224788

Group type: EXPERIMENTAL
Intervention: Sodium sulfacetamide lotion 10%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selenium sulfide lotion 2.5%
Number of subjects: 0
Study: 11513054

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lignocaine 50 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 90
Study: 9267856

Group type: EXPERIMENTAL
Intervention: Idebenone 90 mg t.i.d.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Idebenone 30 mg t.i.d.
Number of subjects: 300
Study: 8289404

Group type: EXPERIMENTAL
Intervention: TPN/GLN
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 29
Study: 2882082

Group type: EXPERIMENTAL
Intervention: Normal alcohol drinking
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low-alcohol beer
Number of subjects: 44
Study: 31464558

Group type: EXPERIMENTAL
Intervention: Booster CYD‐TDV dose (Group 1)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (Group 2)
Number of subjects: 118
Study: 31241683

Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) applied over the left dorsolateral prefrontal cortex and left temporoparietal junction for 10 sessions over 5 consecutive days.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 100
Study: 28290731

Group type: EXPERIMENTAL
Intervention: LBAL (biosimilar adalimumab)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Humira (originator adalimumab)
Number of subjects: 116
Study: 25052130

Group type: EXPERIMENTAL
Intervention: Cefazolin (1 g)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo (10 ml isotonic sodium chloride)
Number of subjects: 299
Study: 24330903

Group type: EXPERIMENTAL
Intervention: High-dose unilateral brief pulse ECT (1.0 millisecond)
Number of subjects: 116

Group type: COMPARATOR
Intervention: High-dose unilateral ultrabrief pulse ECT (0.3-0.4 millisecond)
Number of subjects: 116
Study: 21394895

Group type: EXPERIMENTAL
Intervention: Arm A (6-MP + MTX) in SRG
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Arm B (rotated drug pairs) in SRG
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Arm B (rotated drug pairs) in IRG
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Arm C (6-MP + MTX + VCR + dexamethasone) in IRG
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Overall for all patients
Number of subjects: 429
Study: 18337331

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triclabendazole
Number of subjects: 100
Study: 16966983

Group type: EXPERIMENTAL
Intervention: Intensive psychosocial follow‐up services, family or group therapy, and assisted with substance abuse treatment (n = 56)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard medical treatment and follow‐through in accordance with standard parole or probation procedures (n = 44)
Number of subjects: 100
Study: 15615423

Group type: EXPERIMENTAL
Intervention: Manshuailing oral liquid (CH group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine treatment (RT group)
Number of subjects: 90
Study: 10356669

Group type: EXPERIMENTAL
Intervention: VIP/P-1 (25 micrograms vasoactive intestinal polypeptide combined with 1.0 mg phentolamine mesylate)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: VIP/P-2 (25 micrograms vasoactive intestinal polypeptide combined with 2.0 mg phentolamine mesylate)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: VIP/P-1
Number of subjects: 304
Study: 7490372

Group type: EXPERIMENTAL
Intervention: UVB phototherapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: UVA as placebo
Number of subjects: 17
Study: 1659174

Group type: EXPERIMENTAL
Intervention: mitomycin‐C/ifosfamide (A)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: mitomycin‐C/vindesine (B)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: cisplatin/etoposide (C)
Number of subjects: 192
Study: 7138754

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally every 6 h for a total of five doses prior to diazepam 10 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29883190

Group type: EXPERIMENTAL
Intervention: Patient Navigation with Contingent Financial Incentives (PN+CM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient Navigation without Contingent Financial Incentives (PN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (PN+CM and PN)
Number of subjects: 0
Study: 27160892

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2 through 90)
Number of subjects: 13199

Group type: COMPARATOR
Intervention: Aspirin (300 mg on day 1 followed by 100 mg daily for days 2 through 90)
Number of subjects: 13199

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13199

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 13199
Study: 24346235

Group type: EXPERIMENTAL
Intervention: Ranibizumab + laser photocoagulation (RL group, n=10)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ranibizumab only (Control R group, n=12)
Number of subjects: 22
Study: 22730539

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) at 5 mg/m², repeated after 3 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: No further therapy (control group)
Number of subjects: 120
Study: 20383090

Group type: EXPERIMENTAL
Intervention: Simulation training (3 hours in a simulation laboratory)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Didactic training (3 hours of lectures/video and hands‐on demonstration)
Number of subjects: 0
Study: 18520604

Group type: EXPERIMENTAL
Intervention: Low-dose MDMA (1.0 mg/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-dose MDMA (1.6 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 17187741

Group type: EXPERIMENTAL
Intervention: Health education program (HE) for mothers
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 12483239

Group type: EXPERIMENTAL
Intervention: Dentin‐bonded resin composite (Retroplast, RP)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Glass ionomer cement (Chelon‐Silver, CS)
Number of subjects: 134
Study: 9523420

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 0
Study: 7649973

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2696505

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 20
Study: 350215

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo response)
Number of subjects: 0
Study: 31912605

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31375749

Group type: EXPERIMENTAL
Intervention: Glucose solution (50g/300ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glucose solution with EB
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water with EB
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plain water
Number of subjects: 16

Group type: COMPARATOR
Intervention: Glucose solution without EB
Number of subjects: 16
Study: 29042371

Group type: EXPERIMENTAL
Intervention: Collum Femoris Preserving short stem
Number of subjects: 150

Group type: COMPARATOR
Intervention: Zweymuller Alloclassic conventional stem
Number of subjects: 150
Study: 25664779

Group type: EXPERIMENTAL
Intervention: Counsel and support from district nurses based on empowerment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 23771193

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg single dose in postbariatric surgery group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonsurgical control group
Number of subjects: 10
Study: 22384546

Group type: EXPERIMENTAL
Intervention: Naoxintong Capsule (NC)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Tongguan Capsule
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 104
Study: 19184086

Group type: EXPERIMENTAL
Intervention: Normoxia at 200 W
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hyperoxia at 200 W
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hyperoxia at 150 W
Number of subjects: 12
Study: 16543519

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus stimulation
Number of subjects: 95
Study: 15673175

Group type: EXPERIMENTAL
Intervention: Perspective imposed by language (e.g., 'You are driving a car' or 'You are fueling a car')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Actions directed toward parts of the car (e.g., roof or wheels)
Number of subjects: 0
Study: 11729034

Group type: EXPERIMENTAL
Intervention: Cortisol (15 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 9220521

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 400 micrograms/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 7838188

Group type: EXPERIMENTAL
Intervention: Circulatory arrest
Number of subjects: 171

Group type: COMPARATOR
Intervention: Low-flow bypass
Number of subjects: 171
Study: 2203486

Group type: EXPERIMENTAL
Intervention: Intravenous RO 42-5892 (100 micrograms/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous RO 42-5892 (1000 micrograms/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral RO 42-5892 (600 mg)
Number of subjects: 9
Study: 359383

Group type: EXPERIMENTAL
Intervention: Caroxazone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 40
Study: 31958667

Group type: EXPERIMENTAL
Intervention: Shared a lot treatment (another child shared 6 stickers)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Shared a little treatment (another child shared 1 sticker)
Number of subjects: 2500
Study: 30975923

Group type: EXPERIMENTAL
Intervention: Seribantumab + erlotinib
Number of subjects: 129

Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Seribantumab + erlotinib (in HRG positive patients)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Erlotinib alone (in HRG negative patients)
Number of subjects: 129
Study: 28118028

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) delivered to the tumour bed and regional lymph nodes up to 50.4 Gy (range, 45‐61 Gy)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Observation (no adjuvant treatment)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Resection margin (RM) status
Number of subjects: 59
Study: 24990029

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (normal healthy persons), n = 12
Number of subjects: 17
Study: 22230331

Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 706

Group type: COMPARATOR
Intervention: Ceftriaxone ± linezolid (comparator)
Number of subjects: 706
Study: 20346048

Group type: EXPERIMENTAL
Intervention: Interactive multimedia presentation (IMP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard consent (SC)
Number of subjects: 40
Study: 18705234

Group type: EXPERIMENTAL
Intervention: Bioactive dressing (containing hydrophilic mucopolysaccharide, chitosan)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control dressing (gauze)
Number of subjects: 85
Study: 15615803

Group type: EXPERIMENTAL
Intervention: Idiopathic pulmonary embolism
Number of subjects: 360

Group type: COMPARATOR
Intervention: Pulmonary embolism associated with transient risk factors
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 360
Study: 14500110

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 28
Study: 10562784

Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.3-3.0 mg kg-1 administered pre-emptively i.v. during operation
Number of subjects: 611

Group type: COMPARATOR
Intervention: Fentanyl i.v. for rescue analgesia
Number of subjects: 611
Study: 7479422

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4500
Study: 2110787

Group type: EXPERIMENTAL
Intervention: Intramuscular lorazepam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intramuscular morphine and hyoscine (scopolamine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral lorazepam plus intramuscular morphine and hyoscine
Number of subjects: 30
Study: 426499

Group type: EXPERIMENTAL
Intervention: Cephradine (2 to 4 g per day, administered by intravenous injection in four equally divided doses for a minimum of 4 days)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cefazolin (2 to 4 g per day, administered by intravenous injection in four equally divided doses for a minimum of 4 days)
Number of subjects: 180
Study: 31213163

Group type: EXPERIMENTAL
Intervention: Carotid artery endothelial shear stress in migraine patients
Number of subjects: 40